|
US2018147234A1
|
|
Compositions and methods for treatment of fibromyalgia
|
|
US2016235717A1
|
|
Bendamustine pharmaceutical compositions
|
|
CN104769426A
|
|
Method of treating iron deficiency anemia
|
|
US2013186391A1
|
|
Device for intranasal administration of ketorolac
|
|
US2014162974A1
|
|
Methods for modulation of phosphorus and fgf23
|
|
US2013274650A1
|
|
Stabilized ketorolac compositions
|
|
CN102439071A
|
|
Gaba-linked anthracycline-lipid conjugates
|
|
AU2008203341A1
|
|
Fatty acid-anticancer conjugates and uses thereof
|
|
US2009111774A1
|
|
Pmea lipid conjugates
|
|
KR20180077337A
|
|
Methods and compositions for administration of iron
|
|
US2006116349A1
|
|
Methods and compositions for administration of iron for the treatment of restless leg syndrome
|
|
AU2005201503A1
|
|
Fatty acid-anticancer conjugates and uses thereof
|
|
US2005123504A1
|
|
Bioequivalence test for iron-containing formulations
|
|
AU2004223866A1
|
|
Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
|
|
US6960571B2
|
|
Methods and compositions for administration of iron for the treatment of restless leg syndrome
|
|
WO0056298A2
|
|
Treatment of lyme disease with polysulfated glycosaminoglycan formulations
|
|
US7235583B1
|
|
Fatty acid-anticancer conjugates and uses thereof
|
|
US6293950B1
|
|
Resorbable pin systems
|
|
US5624668A
|
|
Iron dextran formulations
|
|
CA2002643A1
|
|
Antioxidant-free epinephrine solution for ophthalmic use
|
